The "Unfinished Agenda" of infectious diseases is
of great importance to policymakers and research funding agencies that require
ongoing research evidence on their effective management. Journal publications
help effectively share and disseminate research results to inform policy and
practice. We assess research investments to United Kingdom institutions in HIV,
tuberculosis and malaria, and analyse these by numbers of publications and
citations and by disease and type of science.
Information on infection-related research investments
awarded to United Kingdom institutions across 1997-2010 were sourced from
funding agencies and individually categorised by disease and type of science.
Publications were sourced from the Scopus database via keyword searches and
filtered to include only publications relating to human disease and containing
a United Kingdom-based first and/or last author. Data were matched by disease
and type of science categories. Investment (United Kingdom pounds) and
publications were compared to generate an 'investment per publication' metric;
similarly, an 'investment per citation' metric was also developed as a measure
of the usefulness of research.
Total research investment for all three diseases was £1.4
billion, and was greatest for HIV (£651.4 million), followed by malaria (£518.7
million) and tuberculosis (£239.1 million). There were 17,271 included
publications, with 9,322 for HIV, 4,451 for malaria, and 3,498 for
tuberculosis. HIV publications received the most citations (254,949), followed
by malaria (148,559) and tuberculosis (100,244). According to UK pound per
publication, tuberculosis (£50,691) appeared the most productive for
investment, compared to HIV (£61,971) and malaria (£94,483). By type of
science, public health research was most productive for HIV (£27,296) and
tuberculosis (£22,273), while phase I-III trials were most productive for
malaria (£60,491). According to UK pound per citation, tuberculosis (£1,797)
was the most productive area for investment, compared to HIV (£2,265) and
malaria (£2,834). Public health research was the most productive type of
science for HIV (£2,265) and tuberculosis (£1,797), whereas phase I-III trials
were most productive for malaria (£1,713).
When comparing total publications and citations with
research investment to United Kingdom institutions, tuberculosis research
appears to perform best in terms of efficiency. There were more public
health-related publications and citations for HIV and tuberculosis than other
types of science. These findings demonstrate the diversity of research funding
and outputs, and provide new evidence to inform research investment strategies
for policymakers, funders, academic institutions, and healthcare organizations.
Below: Annual research investment for HIV, tuberculosis and malaria
Full article at: http://goo.gl/ilTmkH
By:
- 1Farr Institute for Health Informatics, University College London, 222 Euston Road, London, NW1 2DA, UK. m.head@ucl.ac.uk.
- 2Faculty of Medicine and the Global Health Research Institute, University of Southampton, Southampton, UK. m.head@ucl.ac.uk.
- 3Harvard T.H. Chan School of Public Health, Harvard University, Boston, USA. m.head@ucl.ac.uk.
- 4London School of Hygiene & Tropical Medicine, London, UK. m.head@ucl.ac.uk.
- 5Health Economics Research Group, Brunel University, London, UK. m.head@ucl.ac.uk.
- 6Faculty of Medical Sciences, UCL Medical School, University College London, London, UK. m.head@ucl.ac.uk.
- 7Imperial College London, School of Medicine, London, UK. m.head@ucl.ac.uk.
- 8Northumbria Specialist Emergency Care Hospital, Northumbrian Rd, Cramlington, Northumberland, UK. m.head@ucl.ac.uk.
- 9Johns Hopkins University School of Medicine, Baltimore, USA. m.head@ucl.ac.uk.
More at: https://twitter.com/hiv_insight
No comments:
Post a Comment